What Could Change After Bicycle Therapeutics plc (NASDAQ: BCYC) Gains 63.69% From The High-Point? – Marketing Sentinel
Home  »  Business   »  What Could Change After Bicycle Therapeutics plc (...

What Could Change After Bicycle Therapeutics plc (NASDAQ: BCYC) Gains 63.69% From The High-Point?

Bicycle Therapeutics plc (NASDAQ:BCYC)’s traded shares stood at 2.04 million during the last session. At the close of trading, the stock’s price was $48.69, to imply an increase of 16.76% or $6.99 in intraday trading. The BCYC share’s 52-week high remains $46.25, putting it 5.01% up since that peak but still an impressive 63.69% since price per share fell to its 52-week low of $17.68. The company has a valuation of $1.10B, with an average of 0.39 million shares in intraday trading volume over the past 10 days and average of 212.47K shares over the past 3 months.

Analysts have given a consensus recommendation of a Buy for Bicycle Therapeutics plc (BCYC), translating to a mean rating of 1.70. Of 10 analyst(s) looking at the stock, 0 analyst(s) give BCYC a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 10 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.59.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored

Bicycle Therapeutics plc (NASDAQ:BCYC) trade information

After registering a 16.76% upside in the last session, Bicycle Therapeutics plc (BCYC) has traded red over the past five days. The stock hit a weekly high of 49.91 this Thursday, 10/07/21, jumping 16.76% in its intraday price action. The 5-day price performance for the stock is 17.07%, and 20.07% over 30 days. With these gigs, the year-to-date price performance is 171.25%. Short interest in Bicycle Therapeutics plc (NASDAQ:BCYC) saw shorts transact 0.48 million shares and set a 2.44 days time to cover.

Analysts on Wall Street suggest a consensus price target of $49.80, implying an increase of 2.23% to the stock’s current value. The extremes give us $39.00 and $65.00 for target low and target high price respectively. As such, BCYC has been trading -33.5% off suggested target high and 19.9% from its likely low.

Bicycle Therapeutics plc (BCYC) estimates and forecasts

Looking at statistics comparing Bicycle Therapeutics plc share performance against respective industry, we note that the company has underperformed competitors. Bicycle Therapeutics plc (BCYC) shares are 71.56% up over the last 6 months, with its year-to-date growth rate lower than industry average at -6.02% against 7.00%. Revenue is forecast to shrink -13.50% this quarter before jumping 18.10% for the next one. The rating firms project that company’s revenue will grow 42.10% compared to the previous financial year.

Revenue forecast for the current quarter as set by 8 analysts is $4.61 million. Meanwhile, for the quarter ending Dec 2021, a total of 9 analyst(s) estimate revenue growth to $5.12 million.Earnings reports from the last fiscal year show that sales brought in $3.84 million and $3.85 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 20.00% before jumping 33.10% in the following quarter.

BCYC Dividends

Bicycle Therapeutics plc has its next earnings report out between August 03 and August 09. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Bicycle Therapeutics plc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Bicycle Therapeutics plc (NASDAQ:BCYC)’s Major holders

Bicycle Therapeutics plc insiders hold 16.50% of total outstanding shares, with institutional holders owning 65.89% of the shares at 78.92% float percentage. In total, 65.89% institutions holds shares in the company, led by Tybourne Capital Management (HK) Limited. As of Jun 29, 2021, the company held over 1.96 million shares (or 7.68% of shares), all amounting to roughly $59.44 million.

The next major institution holding the largest number of shares is Sv Health Investors, LLC with 1.92 million shares, or about 7.51% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $58.15 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

We also have Janus Henderson Global Life Sciences Fund and Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund as the top two Mutual Funds with the largest holdings of the Bicycle Therapeutics plc (BCYC) shares. Going by data provided on Jun 29, 2021, Janus Henderson Global Life Sciences Fund holds roughly 0.5 million shares. This is just over 1.94% of the total shares, with a market valuation of $15.06 million. Data from the same date shows that the other fund manager holds a little less at 0.41 million, or 1.61% of the shares, all valued at about 12.3 million.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

173226

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

173226

100% free. stop anytime no spam